Skip to content
Reckitt Benckiser
Search
Join RB’s networks
Facebook
Twitter
RB Early Life Blog
LinkedIn
YouTube
Share
Sitemap
HTML version
Text only version
RB worldwide
Operations around the world
Executive Committee
The Board
RB history
10 years of RB
Contacts
Work & learn at RB
Who we are
Are we right for you?
Your RB career
Our areas of expertise
Graduates
Learn with RB
Career opportunities
Innovators
Products
People
Awards
Our brands
Powerbrands on the shelf
Products around the home
Commercial break
Search RB Brands A-Z
Category performance
Healthcare Brands Employee Reporting
Our responsibility
Environment
Community
Our policies & reports
Investors & media
Reckitt Benckiser offer for SSL-International
Announcements
The talk about RB
Investor information
Category performance
Corporate governance
Share price information
Shareholder information
Contacts
Newsletter Registration
Home
>
Investors & media
>
Announcements
>
2010
>
Response to OFT Statement
Investors & media
Reckitt Benckiser offer for SSL-International
Announcements
The talk about RB
Investor information
Category performance
Corporate governance
Share price information
Shareholder information
Contacts
Newsletter Registration
Announcements
23rd February 2010
Response to OFT Statement
Reckitt Benckiser UK has received the OFT’s preliminary statement regarding Gaviscon. The OFT has stressed that no assumptions should be made at this stage.
RB believes it competes fairly and within the letter and spirit of the law in all of our operations, and has co-operated fully with the OFT throughout its inquiry. Gaviscon Advance is a second generation product, superior to Gaviscon Original.
Gaviscon Advance was launched to provide patients with effective and long lasting relief from heartburn and indigestion. RB will now review the OFT statement and respond accordingly.
Print this page
< prev
Page 1
next >